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Abstract 
Prompted by findings that TGFβ stimulates thymine DNA glycosylase (TDG) 
dependent rapid DNA demethylation and activation of the CDKN2B gene, I investigated the 
global role of TDG and DNA demethylation in TGFβ signaling in HaCaT cells. Using dot 
blot analysis, I show that TGFβ treatment increases the global levels of 5-formylcytosine, an 
intermediate metabolite of active DNA demethylation. Characterization of genomic regions 
that undergo DNA demethylation and recruitment of TDG indicate that they are both 
frequent events, but only overlap at 11 genomic locations. I identified 440 TGFβ upregulated 
genes, 40 of which were bound by TDG and 169 that exhibited DNA demethylation. 
Distribution of the location of TDG peaks and DNA demethylation regions to the gene 
promoter suggests that these events occur at distal elements. These results suggest that TDG 
and DNA demethylation could be important factors involved in TGFβ’s regulation of gene 
expression.  
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1 Introduction 
1.1 Regulation of gene expression 
The proper control of gene expression in a cell-specific and temporal manner is a 
requirement for the normal behaviour of all cells.  Specific sets of genes must be 
dynamically regulated in response to various stimuli and during development. 
Coordinating all of these changes to ensure they occur correctly involves several 
regulatory steps. 
1.1.1 Transcription factors and genomic regulatory elements 
Transcriptional initiation is an important regulatory step that involves the 
assembly of RNA polymerase II (RNAP) and transcription factors to the regulatory 
elements of a gene locus (Maston et al., 2006). Typically, regulatory elements in a gene 
locus include: The promoter, further subdivided into the core promoter, which surrounds 
the transcription start site (TSS), and nearby proximal promoter elements; enhancers and 
silencers, which act at variable distances from a TSS to activate or repress transcription, 
respectively; and insulators, which block the transcriptionally activity of neighbouring 
genes (Figure 1.1). Transcription regulators are bound at these elements and are classified 
as: (1) general transcription factors, which include RNAP and auxiliary components that 
assemble on the core promoter, (2) Sequence specific transcription factors that bind 
directly to DNA at preferred sequences (motifs), and (3) coregulators that are recruited by 
other transcription factors. Transcription factors can promote (activators) and/or suppress 
(repressors) transcriptional activity through various mechanisms, including direct 
interactions with the transcriptional machinery, modifying chromatin structure, and 
recruitment of other transcription factors. Transcription factors and coregulators are 
crucial for the regulation of their target genes. Through this regulation, transcriptional 
regulators are important mediators of all biological processes and their expression 
patterns can dictate cell type and tissue specificity.   
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Figure 1.1. Regulatory elements at a gene locus. Transcription factor binding at the 
following regulatory elements largely dictates the expression of a gene: The promoter, 
which is the sequence surrounding the transcription start site, and enhancers, silencers, 
and insulators which all act distally to the promoter to enhance or repress transcription. 
Figure is adapted from Maston et al., (2006).  
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1.1.2 Chromatin remodeling and histone modifications 
In the cell nucleus, the fundamental repeating unit of chromatin is the nucleosome 
which consists of DNA wrapped around an octamer of histone proteins consisting of 2 
copies each of histones H2A, H2B, H3 and H4. Individual nucleosomes are connected by 
a linker region consisting of DNA and histone H1 and are further packaged into various 
levels of compaction. Chromatin acts as an intrinsic barrier to transcription, by preventing 
access to RNAP and transcription factors to DNA. Therefore, to permit transcription an 
important regulatory mechanism involves the modification and remodeling of chromatin 
and histones. For example, ATP-dependent chromatin remodeling proteins control the 
accessibility of DNA by sliding, ejecting, or restructuring nucleosomes (Narlikar et al., 
2013). A different mechanism involves modification of unstructured histone tails that 
protrude away from the nucleosomal core. Specific residues on these tails are substrates 
for enzymes that catalyze the addition or removal of post translational modifications, 
such as phosphorylation, acetylation, methylation, and ubiquitination. These 
modifications can positively or negatively impact transcription by influencing chromatin 
structure, or by functioning as docking sites for the recruitment of gene regulatory 
proteins. 
1.1.3 DNA methylation 
DNA methylation is an important modification that is found primarily on the 5th 
carbon of cytosine in a CpG dinucleotide, generating 5-methylcytosine (5mC).  5mC 
formation is catalyzed by the DNA methyltransferase (DNMT) enzymes, which transfer a 
methyl group from S-adenosyl methionine (SAM) onto cytosine. Members of the DNMT 
family exhibit distinct functions in mammals: de novo methylation is established by 
DNMT3A and DNMT3B, while methylation on the newly synthesized strand following 
DNA replication is maintained by DNMT1, in association with UHRF1, which recruits it 
to hemimethylated DNA (Bostick et al., 2007; Sharif et al., 2007). DNMT1 and 
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DNMT3A/B are essential enzymes that are required for early development (Li et al., 
1992; Okano et al., 1999).  
The distribution of CpGs and 5mC in the mammalian genome have distinct 
patterns (Smith and Meissner, 2013): (1) The prevalence of a CpG dinucleotide in the 
human genome occurs at much lower frequency than would be expected, (2) some CpGs 
cluster into distinct regions called CpG islands (CGIs), and (3)  non-CGI CpGs are 
usually methylated, while CpGs in CGIs are typically unmethylated. Genomic CpG 
depletion can be explained by the susceptibility for methylated cytosine to undergo 
deamination to thymine, resulting in a reduction of non-CGI CpGs over time.  
Cytosine methylation alters the biochemical properties of DNA, which can 
negatively impact transcription depending on the genomic context. Strikingly, 
approximately 60% of all gene promoters contain CGIs (Deaton and Bird, 2011). CGI 
core promoters within transcriptionally active genes are often depleted of nucleosomes, 
but are usually flanked by the H2A.Z histone variant and high levels of H3K4me3 
(Deaton and Bird, 2011; Jones, 2012). Inactive CGI promoters are often nucleosome rich 
and contain high levels of H3K27me3 and H3K4me3 marks (Jones, 2012; Schübeler, 
2015). The majority of CGI within promoters are unmethylated regardless of gene 
activity, which may, in part, be maintained by H3K4me3, which antagonizes DNMT 
recruitment (Ooi et al., 2007; Schübeler, 2015). However, in imprinted genes, X 
chromosome inactivation, and in heterochromatin containing repetitive elements and 
transposons, DNA hypermethylation serves an important function in long-term silencing 
(Jones, 2012). DNA methylation contributes to transcriptional silencing by interfering 
with the binding of some transcription factors and/or by recruiting transcriptional 
repressors that selectively bind 5mC.  
Methylation is also important at genomic elements other than CGI promoters. 
Although the genome-wide relationship between methylation of promoters not associated 
with a CGI and expression is unclear, these promoters do exhibit cell-type specific 
methylation (Jones, 2012). Enhancers often have variable DNA methylation levels and 
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undergo genome-wide demethylation upon activation of transcription (Blattler et al., 
2014; Jones, 2012; Wiench et al., 2011). Furthermore, reporter assays have shown that 
methylation of enhancer regions reduces transcriptional activity (Schmidl et al., 2009; 
Wiench et al., 2011). Finally, gene bodies are commonly methylated in actively 
transcribed genes (Jones, 2012). In this context, DNA methylation may have a role in 
regulating splicing (Lev Maor et al., 2015).  
 Methylation patterns are dramatically altered in cancer. Cancer cells often exhibit 
genome-wide hypomethylation that primarily occurs in repetitive regions, and contributes 
to genomic instability (Robertson, 2005). In contrast, DNA hypermethylation of CGI 
promoters in tumour suppressor genes, such as MGMT, RB1, and BRCA1, is associated 
with transcriptional silencing (Esteller, 2007). The molecular basis for aberrant 
methylation in cancer is not completely understood. 
1.2 DNA demethylation 
Removal of the 5mC mark (DNA demethylation) can occur through two general 
mechanisms: Passive demethylation, which involves the loss of 5mC during successive 
rounds of replication in the absence of functional DNA methylation maintenance 
machinery, and active DNA demethylation, an enzymatic process that removes or 
modifies the methyl group from 5mC. The importance of these mechanisms were initially 
recognized during embryonic development. Shortly after fertilization, the maternal 
genome undergoes passive DNA demethylation that is dependent on DNA replication. In 
contrast, the paternal genome is rapidly demethylated prior to the first cell division 
suggesting that the process is active (Smith and Meissner, 2013). 
1.2.1 TET mediated DNA demethylation 
The discovery of a family of enzymes that can modify 5mC into 5-
hydroxymethylcytosine (5hmC) has greatly advanced our understanding of DNA 
demethylation mechanisms. This discovery was motivated in large part, by work on the 
biosynthesis of Base J in Trypanosoma brucei (Borst and Sabatini, 2008). Production of 
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Base J involves oxidation of thymine to 5-hydroxymethyluracil (5hmU) by J binding 
protein 1 (JBP1) and JBP2, members of the Fe(II)/α-ketoglutarate (α-KG)-dependent 
oxygenase family of enzymes. Bioinformatic analyses identified mammalian orthologues 
of JBP1 and JBP2  that belong to the ten-eleven translocation (TET) family (Tahiliani et 
al., 2009). The same study demonstrated that TET1 catalyzes oxidization of the methyl 
group of 5mC, generating 5hmC. It was later determined that 5hmC can be iteratively 
oxidized into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) by the TET enzymes 
(Ito et al., 2011). 5hmC, 5fC, 5caC, collectively called methylcytosine oxidized 
metabolites, can accumulate in some tissues and can be diluted through successive DNA 
replications, as is the case for 5hmC during preimplantation development (Inoue and 
Zhang, 2011; Wu and Zhang, 2014). Alternatively, in vitro assays show that 5fC and 
5caC are specifically recognized and excised by thymine DNA glycosylase (TDG) (He et 
al., 2011; Maiti and Drohat, 2011). TDG excision of 5fC/5caC generates an abasic site 
that is processed by the base excision repair (BER) pathway, which replaces the abasic 
site with cytosine (Figure 1.2). This mechanism is further supported by studies showing 
that 5fC/5caC accumulate in TDG depleted mESCs (Shen et al., 2013). 
TET1 expression is found primarily in embryonic stem cells, and is 
downregulated following differentiation. In contrast, TET2 and TET3 are ubiquitously 
expressed in adult tissues. TET mediated oxidation involves a base flipping mechanism, 
which positions the cytosine derivative in the catalytic site (Shen et al., 2014). The 
reaction involves molecular oxygen, α-KG, and Fe(II) to generate a Fe(IV)-oxo 
intermediate that acts on 5mC, 5hmC, or 5fC to generate the subsequent metabolite. 
Common to all three TET proteins is the catalytic domain at the C-terminal end (Shen et 
al., 2014). The core of the catalytic domain is a double stranded β-helix (DSBH) fold 
composed of eight anti-parallel β-strands. The amino –terminus of TET1 and TET3, but 
not TET2, contain a CXXC (cysteine-X-X-cysteine) domain (Shen et al., 2014). In vitro 
binding assays have shown that the TET1 and TET3 CXXC domains bind preferentially 
to CG rich DNA (Xu et al., 2012; Zhang et al., 2010), which suggests that this domain 
may be important for targeting TET1/3 to specific sequences. All three TET proteins are 
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O-GlcNAcylated, which promotes nuclear export of TET3 (Bauer et al., 2015; Chen et 
al., 2013; Shi et al., 2013; Zhang et al., 2014). Mass spectrometry analysis identified that 
TETs can also be phosphorylated, which is reduced by increased O- GlcNAcylation, 
suggesting that there is an interplay between these modifications (Bauer et al., 2015).  
A fusion of the amino terminal region of TET1 with the histone methyltransferase 
mixed lineage leukemia (MLL) has been identified in several cases of acute myeloid 
leukemia (AML) (Shen et al., 2014). Mutation of TET2 is highly prevalent in chronic 
myelomonocytic leukemia (CML), AML, and myelodysplastic syndromes (MDS), and 
deletion of TET2 in mice leads to the development of myeloid malignancies (Huang and 
Rao, 2014; Li et al., 2011). Also, global levels of 5hmC are reduced in a number of 
different cancers (Lian et al., 2012; Yang et al., 2012). Thus, TET proteins are believed to 
function as tumour suppressors (Shen et al., 2014). 
1.2.2 Methylcytosine oxidized metabolites are potential functional epigenetic 
marks 
In addition to functioning as metabolic intermediates, genome-wide studies 
indicate that 5mC derivatives can accumulate at some regions of the genome suggesting 
that they represent epigenetic marks that are important for transcription. In embryonic 
stem cells (ESCs), 5hmC is enriched at active distal enhancers, gene bodies, and in the 
promoters of low to medium expressing genes, while 5fC/5caC are enriched at enhancers 
containing both activating and repressive histone modifications (poised enhancers) (Song 
and He, 2013; Song et al., 2013a; Wu and Zhang, 2014; Yu et al., 2012). Interestingly, in 
the absence of TDG, 5fC/5caC accumulate at active distal enhancers in ESCs (Shen et al., 
2013; Song et al., 2013a). This accumulation at regulatory elements is believed to occur 
through recruitment of TETs and TDG by transcription factors to these particular regions 
(Song and He, 2013; Wu and Zhang, 2014). 
  Mass-spectrometry-based proteomic approaches have identified specific readers 
for each 5mC modification in mESCs and adult mouse brain tissue (Iurlaro et al., 2013; 
Spruijt et al., 2013). Importantly, each cytosine modification recruits a distinct set of 
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proteins with known functions in transcriptional regulation and active demethylation. In 
vitro studies have shown that RNAP elongation efficiency is reduced when a DNA 
template contains 5fC or 5caC, but unaffected when the template contains cytosine, 5mC, 
or 5hmC (Kellinger et al., 2012). This was also observed in 293T cells (You et al., 2014). 
Collectively, these studies indicate that the oxidized metabolites have important 
regulatory functions in gene expression. 
1.2.3 AID/APOBEC mediated DNA demethylation 
An alternative pathway resulting in DNA demethylation has also been proposed 
involving deamination (removal of an amine group) by Activation-Induced Deaminase 
(AID)/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) 
enzymes (figure 1.2). AID was previously known to be involved in antibody diversity by 
mediating the error prone process of deamination of cytosine to uracil followed by repair 
of the U:G mismatch by TDG/BER pathway or the mismatch repair pathway (Bhutani et 
al., 2011). An in vitro study demonstrated that AID/APOBEC can act on 5mC and 
deaminate this DNA base to thymine (Morgan et al., 2004). Overexpression of AID and 
the glycosylase methyl-CpG binding domain 4 (MBD4) in zebrafish caused 
demethylation of the genome and an injected methylated DNA construct (Rai et al., 
2008). AID/APOBEC mediated demethylation has been identified in primordial germ 
cells, pluripotency reprogramming, and the epithelial-mesenchymal transition (EMT) 
(Bhutani et al., 2010; Munoz et al., 2013; Popp et al., 2010). Also, AID/APOBEC 
overexpression leads to demethylation of a co-transfected 5hmC-containing reporter 
plasmid and increased levels of 5-hydroxymethyluracil (5hmU), a deaminated product of 
5hmC, in HEK293 cells (Guo et al., 2011). Collectively, these studies have demonstrated 
a role for AID in DNA demethylation by meditating deamination of 5mC and 5hmC. 
However, since these discoveries, the feasibility of these deamination mechanisms has 
been put into question by an in vitro study demonstrating that the enzymes greatly favour 
cytosine as their substrate over modified cytosine (Nabel et al., 2012; Wu and Zhang, 
2014). 
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Figure 1.2. DNA demethylation mechanisms. In passive DNA demethylation, the loss 
of 5mC or its metabolites occurs through successive rounds of DNA replication in the 
absence of functional DNA methylation maintenance machinery. Active DNA 
demethylation can occur through: (1) TET1/2/3 iterative oxidization of 5mC to 5hmC, 
5fC, and 5caC, followed by TDG excision of 5fC and 5caC and replacement of the abasic 
site with cytosine via the BER pathway, or (2) AID/APOBEC mediated deamination of 
5mC to thymine, or 5hmC to 5hmU, followed by TDG excision and BER processing. 
Figure is from (Bhutani et al., 2011). 
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1.2.4 TDG 
TDG is a member of the uracil DNA glycosylase (UDG) family of enzymes and 
was originally identified as a component of the BER pathway involved in DNA repair. 
TDG contains a catalytic glycosylase domain that recognizes and excises thymine from a 
G:T lesion and also uracil from a G:U mismatch generating an abasic site (Xu et al., 
2015). Because TDG is tightly bound to the abasic site, the dissociation of TDG from the 
abasic site is the rate-limiting step of the reaction (Sjolund et al., 2013). 
Apurinic/apyrimidinic endonuclease (APE1) binds to TDG and promotes its dissociation 
from the abasic site (Waters et al., 1999). Sumoylation of TDG also promotes its 
dissociation (Sjolund et al., 2013). After TDG is released, APE1 cleaves the DNA 
backbone generating a single nucleotide gap that is filled in by DNA polymerase β (pol 
β) and sealed by DNA ligase (Sjolund et al., 2013; Xu et al., 2015).  
 As previously mentioned, TDG can recognize and excise 5fC, 5caC and the G:T 
mispair generated by deamination of 5mC. In addition, TDG can excise 5hmU 
(Cortellino et al., 2011). Interestingly, TDG interacts with DNMT3A and an in vitro 
assay showed that TDG represses the methyltransferase activity of DNMT3A (Li et al., 
2007). TDG also associates with AID and all three TET proteins (Cortellino et al., 2011; 
Müller et al., 2014). Thus, TDG has a central role in DNA demethylation. 
TDG has an important role in gene expression by acting as an essential 
transcriptional coactivator. TDG directly associates with cAMP response element-
binding protein (CBP) and enhances CBP transcriptional activity (Tini et al., 2002). TDG 
has been shown to associate with numerous transcriptional regulators and nuclear 
receptors, including the estrogen receptor alpha (ERα), retinoic acid receptor alpha 
(RARα), steroid receptor coactivator-1 (SRC1), and transcription factor 4 (TCF4) (Chen 
et al., 2003; Jia et al., 2014; Léger et al., 2014; Lucey et al., 2005). It is currently unclear 
if TDG’s transcriptional coactivator function is coupled to its role in DNA demethylation.  
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TDG null embryos die around E12.5 suggesting that it plays an important role in 
development (Cortázar et al., 2011; Cortellino et al., 2011). This makes TDG unique 
from other UDG family members (uracil DNA glycosylase (UNG), MBD4, single-strand-
selective monofunctional uracil-DNA glycosylase 1 (SMUG1)), which are all dispensable 
for embryonic development (Wu and Zhang, 2014). Expression of developmental genes 
was impaired in TDG null mice, attributed to histone modifications changes, altered 
recruitment of CBP and MLL, and gene promoter hypermethylation (Cortázar et al., 
2011; Cortellino et al., 2011). In contrast, DNA repair was deemed unaffected. These 
findings demonstrated a pivotal role for TDG in maintaining epigenetic stability during 
development. 
1.3 The TGFβ signaling pathway 
The combination of transcription factors, coregulators, histone modifications, and 
DNA methylation play a crucial role in controlling gene expression. Many of these 
factors can be controlled through signal transduction pathways to elicit a change in gene 
expression. One important example is the transforming growth factor beta (TGFβ) 
pathway. 
1.3.1 TGFβ signaling system 
TGFβ is a cytokine that drives cell-type specific gene expression changes to 
regulate cell proliferation, apoptosis, development, and homeostasis. The signaling 
pathway is composed of different ligand isoforms, membrane bound receptors, 
transcription factors, coregulators, and chromatin modifiers. In this thesis, the focus is on 
the TGFβ1 ligand. The canonical TGFβ activated ligand binds to TGFβ receptor 
complexes containing serine/threonine kinases, which induces receptor trans-
phosphorylation and kinase activation. Next, the TGFβ type 1 receptor (TβR1) 
phosphorylates SMA- and MAD-related 2 (SMAD2) and SMAD3 (receptor activated 
SMADS, R-SMADs), promoting oligomerization of R-SMADs with SMAD4. Upon 
complex formation, R-SMADs/SMAD4 are translocated into the nucleus, where they 
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bind directly to DNA, and associate with many other transcription regulators to regulate 
the expression of hundreds of genes.  
However, that does not depict the whole story and additional features complicate 
TGFβ signaling. A negative feedback loop is established by genes that are induced by 
TGFβ and inhibit the signaling pathway. For example, SMAD7 expression is induced by 
TGFβ and competitively inhibits phosphorylation of R-SMADs, recruits phosphatases to 
inactivate the receptors, and promotes ubiquitination and subsequent degradation of 
TβR1 (Pardali and Moustakas, 2007). Also, different combinations of the signal 
transduction components and transcriptional regulators, as well as the epigenetic 
landscape comprise the ‘contextual determinants of TGFβ action’, which largely dictates 
how a cell will respond to TGFβ (Massagué, 2012). Finally, TGFβ can activate other 
signaling pathways (e.g. MAPKs, PI3K) and other signaling pathways can activate the 
SMADs. 
1.3.2 TGFβ transcriptional mechanisms and responses 
SMADs are an example of transcription factors that can either activate or repress 
transcription. This is achieved by associating with a number of different DNA binding 
transcription factors and coregulators. Commonly associated transcription factors include 
specificity protein 1 (SP1), CCAAT/enhancer binding protein (C/EBPβ), nuclear factor-
kappaB (NF-κB) and members of the forkhead box (FOX), runt-related transcription 
factor (RUNX), and activating protein 1 (AP1) families (Massagué et al., 2005; Ross and 
Hill, 2008). Transcriptional coregulators involved include p300, CBP, and p300/CBP 
associated factor (P/CAF), p107, and various histone deacetylases (HDACs) (Massagué 
et al., 2005). Brahma-related gene-1 (BRG1), an ATP dependent chromosome 
remodelling complex, directly interacts with SMAD2 and SMAD3 and plays an 
important role in TGFβ transcriptional activation and repression (Xi et al., 2008). Thus, a 
multitude of transcription factors, coregulators and chromatin modifiers are involved in 
TGFβ’s gene expression program.  
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TGFβ orchestrates a cytostatic response in epithelial, endothelial, and 
hematopoietic cells (Pardali and Moustakas, 2007). This response results in arrest in the 
cell cycle at G1 and is achieved by multiple mechanisms. A key step is the TGFβ-
dependent recruitment of SMAD3, p107, and E2F4 to the c-MYC promoter, 
downregulating this mitogenic transcription factor (Chen et al., 2002). TGFβ also induces 
SMAD mediated transcriptional repression of inhibitor of differentiation family members 
(ID1/2/3), which is necessary for TGFβ growth arrest (Kang et al., 2003; Pardali and 
Moustakas, 2007). Transcriptional induction of cyclin dependent kinase inhibitors (CKIs) 
is also a key mechanism used by TGFβ to arrest the cell cycle. In a complex with SP1, 
the SMADs bind to the promoters of cyclin dependent kinase inhibitor 2B (CDKN2B, 
also called p15) and cyclin dependent kinase inhibitor 1A (CDKN1A, also called p21) to 
dramatically upregulate their transcription (Feng et al., 2000; Pardali et al., 2000).  
In EMT, epithelial cells lose cell-cell junctions and change polarity, while at the 
same time reorganizing the cytoskeleton, acquiring motile and invasive capabilities, and 
ultimately, adopt a mesenchymal phenotype (Lamouille et al., 2014). TGFβ induces EMT 
in multiple cell types primarily by upregulating several transcription factors involved in 
promoting EMT. For example, TGFβ treatment upregulates snail zinc finger 1 (SNAIL), 
snail zing finger 2 (SLUG), zinc finger E-box binding homeobox 1 and 2 (ZEB1/2) 
transcription factors, and stimulates them to localize to the epithelial cadherin (E-
Cadherin or ECAD) promoter and repress ECAD transcription via recruitment of 
repressive complexes (Xu et al., 2009). The downregulation of ECAD, an adherens 
junction protein, is a hallmark event in EMT.  Many additional transcriptional changes 
occur in TGFβ induced EMT that ultimately result in the downregulation of epithelial 
markers and upregulation of mesenchymal markers (Xu et al., 2009). 
In addition to growth arrest and EMT, TGFβ can also promote apoptosis, regulate 
angiogenesis, and modulate immune cells (Tian et al., 2011). Thus, TGFβ has many 
tumour promoting and tumour suppressive effects. Importantly, cancer cells often find a 
way to inactivate the tumour suppressive axis, while still enabling the tumour promoting 
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functions of TGFβ (Kubiczkova et al., 2012). An understanding of the mechanisms 
behind this switch is an important area of research in order to properly target TGFβ and 
its paradoxical functions in cancer. 
1.4 Rationale & hypothesis 
Previous work in my lab showed that the CDKN2B promoter is rapidly 
demethylated in response to TGFβ treatment in HaCaT cells (Thillainadesan et al., 2012). 
TDG, AID, and BER components were recruited within 90 minutes of TGFβ treatment 
and TDG was required for the TGFβ-dependent demethylation and induction of 
CDKN2B. In addition, 5hmC accumulated on the CDKN2B promoter in TDG depleted 
cells. This work presented a mechanism whereby TGFβ treatment stimulates oxidation 
and/or deamination of 5mC at the CDKN2B promoter in conjunction with TDG 
recruitment and processing of the 5mC metabolites. Dot blot analysis also showed that 
global 5mC levels are decreased by TGFβ in a TDG-dependent manner (Thillainadesan et 
al., 2012). This finding prompted the hypothesis for my project: TDG dependent DNA 
demethylation is a global mechanism used to regulate TGFβ induced gene 
expression. The objectives to test this hypothesis were as follows: 
1) Assess global TGFβ induced changes in the oxidized methylcytosine 
metabolites. 
2) Characterize global TGFβ dependent TDG binding and DNA 
demethylation and their relationship with gene expression. 
3) Determine if TDG is essential for TGFβ-dependent growth arrest and 
EMT induction. 
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Figure 1.3. The canonical TGFβ signaling pathway. TGFβ ligand binding to its 
receptors induces activation of the receptor’s kinase domain. SMAD2/3 are then 
phosphorylated by the activated TGFβ receptor, promoting oligomerization with SMAD4 
and entry into the nucleus. In the nucleus, SMADS associate with numerous 
transcriptional regulators to activate or repress transcription of hundreds of genes. A 
negative feedback loop is established by induction of genes (e.g. SMAD7, Smurfs) that 
inhibit SMAD2/3 phosphorylation or target components of the pathway for degradation. 
Figure is adapted from (Pardali and Moustakas, 2007). 
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2 Materials & Methods 
2.1 Cell culture, TGFβ treatments, and transfections 
HaCaT cells and mouse embryonic fibroblasts (MEFs) were cultured in 
Dulbecco’s modified Eagle medium (DMEM), supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin (all from Wisent). For EMT experiments, media 
for HaCaT cells was changed to low calcium DMEM for at least 48 hours prior to 
treatment. All cells were maintained in a 37˚C incubator with 5% CO2. For TGFβ (R&D, 
240-B) treatments, HaCaT cells were grown to approximately 60% confluency and serum 
starved (0% FBS) for 24 hours. Media was then replaced with DMEM containing 10% 
FBS and 5ng/mL TGFβ or vehicle (4 mM HCl containing 0.1% human BSA). For 
transfections, HaCaT cells were seeded overnight and transfected using Lipofectamine 
2000 and control siRNA (Dharmacon, D-001210-03-50) or siTDG (Dharmacon, M-
040665-01). To excise TDG in Tdgflox/flox;UB-Cre/ERT2+ MEFs, cells were treated with 
100 nM tamoxifen for 48 hours. 
2.2 Dot blot analysis of 5mC, 5hmC, and 5fC 
Genomic DNA was isolated from HaCaT cells using the GeneElute Mammalian 
Genomic DNA miniprep kit (Sigma, G1N70). DNA samples were denatured at 100˚C for 
10 minutes in 0.1 M sodium hydroxide, crunched on ice for 5 minutes, and then 
neutralized with 1/10th the volume of cold 6.6M ammonium acetate. DNA was then 
applied to a positively charged nylon membrane (Hybond N+, RPN2020B) using a 
filtration manifold (Schleicher & Schuell). The membrane was then baked in an 80˚C 
oven under vacuum for 30 minutes, incubated in blocking buffer (5% milk, PBS, 0.1% 
Tween-20) for one hour, and incubated with the following antibodies overnight at 4˚C in 
blocking buffer: anti-5mC (1:2000, Millipore, 33D3), anti-5hmC (1:1000, Active Motif, 
39769), and anti-5fC (1:1000, Active Motif, 61223). The membrane was then washed 
several times, incubated with secondary antibodies (1:10,000, anti-Mouse (GE, NA931V) 
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or anti-Rabbit (GE, NA934V) for 1 hour, and washed again, all in blocking buffer.  The 
chemiluminescent signal was detected using Enhanced chemiluminescence (ECL) 
(Millipore, WBLUF0100) and a chemidoc MP system. After imaging, the membrane was 
incubated in 0.02% methylene blue with 0.3M sodium acetate, followed by destaining in 
water. 
2.3 ChIP-Seq, MeDIP-Seq, and RNA-Seq 
The DNA for the ChIP-Seq and MeDIP-Seq experiments were prepared as 
described in Thillainadesan, et al. (2012), except that lysates were pre-cleared by an IgG 
antibody to reduce non-specific binding. HaCaT cells were serum starved and treated 
with TGFβ for 90 minutes for the ChIP and 3 hours for the MeDIP. Library construction, 
Illumina HiSeq sequencing (75 base pair paired-end reads), and sequence alignment of 
the ChIP and MeDIP samples (untreated and treated) was conducted at the Michael Smith 
Genome Sciences Centre at the British Columbia Cancer Agency (Vancouver, BC). I 
conducted validations of the ChIP-Seq as described in Thillainadesan, et al., (2012), 
except that a commercial antibody for TDG (Thermo Scientific, PA5-29140) was used 
and a 5 minute incubation with 0.125 M glycine was included after formaldehyde cross-
linking. Primer sequences for ChIP-qPCR are listed in 2.9. 
Cell treatments and RNA isolation for the RNA-Seq experiment were conducted 
by Majdina Isovic. HaCaT cells were serum starved and then treated with TGFβ, or 
vehicle, for 3 and 16 hours. RNA was collected using RNeasy kit (Qiagen, 74104). RNA 
integrity was assessed by an Agilent 2100 Bioanalyzer at the London Regional Genomics 
Centre at Robarts Research Institute (London, ON). Library construction and sequencing 
using Illumina HiSeq platform (101 base pair paired-end reads) was conducted at The 
Centre for Applied Genomics at The Hospital for Sick Children (Toronto, ON). I 
conducted RNA-Seq validations as described above. cDNA was reversed transcribed 
using a reverse transcription using High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, 4368814) followed by SYBR-green based qPCR (Applied 
Biosystems, 4367659). Primer sequences are listed in 2.9. 
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2.4 ChIP-Seq data analysis 
Bioinformatic analysis of aligned reads (hg19) was completed using Partek 
Genomic Suite 6.6 (PGS). Only reads that were of sufficient quality and aligned 
unambiguously were used. To detect ChIP-Seq peaks, the genome was divided into 200 
base pair windows and midpoints of peaks within a window were counted and an 
empirical distribution of window counts was created. PGS uses a zero truncated binomial 
model to fit the distribution and calculate a false discovery rate (FDR). 29,191 peaks with 
a FDR less than 0.01 were scored. To identify TGFβ dependent TDG recruitment, peaks 
containing a greater than 2 fold scaled fold change between treatment and control were 
used in downstream analysis (3364 peaks). Scaled fold change compares the intensity of 
signal of the TGFβ sample to the control sample and is scaled by a ratio of the number of 
total alignments of each sample on a per chromosome basis. PGS, which uses the Gibbs 
motif sampler, was used for de novo motif analysis using the default parameters. Known 
motif analysis was conducted using the JASPAR database. CpG islands were downloaded 
from the ENCODE database. RefSeq (2014-10-17) was used to annotate location of a 
peak to a genomic feature, defining the promoter as -50 kbp to +3kbp or -5kbp to +3kbp, 
as indicated. Gene Ontology analysis was conducted as described in 2.6. 
2.5 MeDIP-Seq data analysis 
Bioinformatic analysis of aligned reads (hg19) was completed using PGS. Only 
reads that were of sufficient quality and aligned unambiguously were used. Differentially 
methylated regions (DMRs) were detected using 200 base pair windows and FDR of 
0.001. To identify TGFβ dependent regions with a methylation loss, only regions 
containing a greater than 2 fold methylation loss after treatment were used in downstream 
analysis (8230 peaks). All other analysis was conducted similarly to the ChIP-Seq. 
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2.6 RNA-Seq data analysis 
RNA-Seq raw reads were filtered and aligned to hg19 using TopHat2 (2.0.11) and 
summarized to RefSeq (2014-10-17) transcripts using default parameters. Reads Per 
Kilobase of exon model per Million mapped reads (RPKM) was used to normalize 
between samples and values were compared between TGFβ and control to identify genes 
that were up or down regulated at each time point. Gene Ontology (GO) analysis was 
conducted in PGS using the fisher’s exact test and excluded functional groups containing 
less than 10 genes.   
2.7 Protein extraction, Western blot, antibodies 
Cells were washed twice in phosphate-buffered saline (PBS), harvested and lysed 
in RIPA lysis buffer consisting of 0.15M NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS, and 50 mM tris (pH 8), and protease inhibitor cocktail. The lysates were 
incubated on ice for 20 min and then centrifuged for 15 min at 15,000 rpm at 4˚C to 
remove insoluble cellular material. The supernatant was retained and protein 
concentrations were determined using Bradford assay. Samples were normalized for 
protein content and were separated by SDS-PAGE, transferred to PVDF membrane and 
incubated overnight in blocking buffer (see 2.2). The appropriate antibodies were then 
diluted in blocking buffer and the membrane was probed for 2 hr at room temperature 
with rocking, followed by  addition of the appropriate secondary antibody (1:10 000 
dilution) for 1 hr. Proteins were detected using ECL according to the manufacturers 
recommendations (Millipore, WBLUF0100). Blots were quantified using Image Lab 
Software (Bio Rad, #1709690). The following antibodies were used: TDG (Thermo 
Scientific, PA5-29140), TDG (gift from Marc Tini, used for detection of mouse TDG 
only), Vinculin (Sigma, V9264), p15 (Santa Cruz, C-20), E-Cadherin (BD Biosceinces, 
610181), and N-Cadherin (BD Biosciences, 610920). 
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2.8 Growth curve 
72 hours post-transfection, HaCaT cells were seeded at 125, 000 cells/well in a 6 
well dish and treated with TGFβ or vehicle four hours later. Cells were trypsinized every 
24 hours post treatment and a cell concentration was determined using a hemocytometer. 
MEFS were treated for 48 hours with 100 nM tamoxifen to induce excision of TDG. 
Cells were then harvested and seeded overnight in a 6 well dish. Cell number was 
counted the next day and used as the number of cells at time 0. Cells were then treated 
with vehicle or TGFβ and cell concentration was counted every 24 hours post-treatment 
using a MOXI Z Mini Automated Cell Counter (ORFLO, MXZ001). 
2.9 Primer sequences 
RNA analysis 
Gene  Forward 5’-3’ Reverse 5’-3’ 
GAPDH GTTTCTATAAATTGAGCCCGCAG CGACCAAATCCGTTGACTCC 
TDG CAAATGGGCTAATTGAGAGCCGT CAAACTAGGTTCTACTTGTGAC 
EREG ACAGCTTTAGTTCAGACAGAAGAC CATCGGACACCAGTATAACCC 
SIRPA CGGAACATCTATATTGTGGTGGG TCATGCAACCTTGTAGAGAAGTG 
IFIT2 AGCATTTATTGGTGGCAGAAGAG TATTGTTCTCACTCATGGTTGCA 
PDZK1 CATCTCCAGAAATGACCTCCA ATTCCCACTCTTTATGACCA 
PIK3IP1 CCAGAACAGCATAACAAGGG CAGAAACAGCCTCCAGATCC 
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ChIP-qPCR analysis 
Gene  Forward 5’-3’ Reverse 5’-3’ 
MMP9 CCTGATCAACATGGAGAAACCC AAGAGTTTCCGCTGTTGTTCC 
COL4A2 GCATGGGAAGAGGAAGAAGAC CTCGTTTCCCTCCATTGTTCTC 
AK8 GCAATTCCTCCAACAATCAATGTG GGGTTAGAAGTCAGCAGGTC 
HAS2 AGACTTCCTACCTTTATCCAAGAG GCATTATTAGGACTGATAGCGA 
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3 Results 
3.1 TGFβ-dependent changes in global 5mC oxidized metabolites 
Previous studies have shown that a 90 minute TGFβ treatment decreases global 
levels of 5mC in HaCaT cells (Thillainadesan et al., 2012). Importantly, the 5mC 
decrease was TDG dependent, raising the possibility that this decrease involves a TDG 
mediated active DNA demethylation pathway. To assess whether the TET/TDG active 
demethylation pathway is regulated by TGFβ, I used a dot blot assay to monitor changes 
in 5mC oxidized metabolites. The dot blot assay involves immobilization of DNA onto a 
membrane, followed by a traditional western blot procedure using a primary antibody 
that is specific for 5mC, 5hmC, or 5fC.  Preliminary experiments were necessary in order 
to validate the consistency of the assay by analyzing signal intensity of serially diluted 
DNA samples using 5mC, 5hmC, and 5fC antibodies (Figure 3.1A). Following 
validation, I confirmed that global 5mC decrease occurs after a 3 hour TGFβ treatment in 
HaCaT cells (Figure 3.1B, left). Next, I used this time point to assess TGFβ-dependent 
global changes in 5hmC and 5fC. TGFβ caused a slight but consistent global decrease in 
5hmC levels (Figure 3.1B, middle). Interestingly, while both 5mC and 5hmC are 
decreased by TGFβ, a 3-fold global increase in 5fC was also observed (Figure 3.1B, 
right). Collectively, these results suggest that DNA demethylation mechanisms are 
regulated globally in response to TGFβ signaling and shows for the first time a signal 
directed change in 5fC. 
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Figure 3.1. TGFβ causes rapid global changes of oxidized 5mC metabolites in 
HaCaT cells. A) Validation of the dot blot assay. Serial dilutions of DNA were applied 
to a nylon membrane in duplicate and probed with the indicated antibodies. B) Dot blot 
analysis of genomic DNA isolated from HaCaT cells treated with or without TGFβ 
(5ng/mL) for 3 hours. Methylene Blue is used as a control for DNA loading. Blots are 
representative of three independent experiments. 
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3.2 Genome-wide Analysis of TDG recruitment and DNA demethylation 
To identify the genomic locations where active demethylation occurs as well as 
understand its importance to TGFβ signaling, an approach was taken using ChIP-Seq, 
MeDIP-Seq, and RNA-Seq methodologies in TGFβ treated HaCaT cells (Figure 3.2). 
The use of HaCaT cells for this study is warranted because they are a non-tumourigenic 
cell line that is TGFβ responsive (Boukamp et al., 1988), which allows for investigation 
of the signaling network under a more ‘normal’ physiology as compared to cancer cells. 
Additionally, HaCaT cells are a well validated model system previously used to 
characterize TGFβ-dependent gene regulation (Levy and Hill, 2005; Xi et al., 2008; 
Zavadil et al., 2001). 
Genomic locations for TDG were identified using ChIP-Seq in control and TGFβ 
treated HaCaT cells (90 min). This time point was chosen based on previous experiments 
by my lab demonstrating maximal recruitment of TDG at the CDKN2B promoter 
following a 90 minute TGFβ treatment (Thillainadesan et al., 2012). Approximately 200 
million reads were obtained for each sample and after filtering, the remaining reads were 
aligned to the human genome. Peaks were detected using an FDR of 0.01 and a window 
size of 200 bps. A 2-fold increase in signal intensity between the TGFβ sample and the 
untreated was used as the cutoff.  Based on this analysis, 3364 TGFβ dependent peaks 
were identified (Figure 3.3A).  
Remarkably, the CDKN2B locus, located on chromosome 9, exhibited a 566 fold 
increase in TDG binding (Figure 3.3C). This peak had the greatest fold change between 
TGFβ-treated and untreated cells, with the next highest fold change being 23. Analysis of 
the distribution of TDG binding along individual chromosomes indicated that TDG 
recruitment is not dependent on chromosome size, suggesting that the binding is not 
random (Figure 3.3B). It also revealed a strong preference for TDG recruitment on 
chromosome 9. To investigate if TDG recruitment is occurring at CpG islands, a mapped 
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list of CpG islands was downloaded from the ENCODE database. Surprisingly, TDG 
recruitment overlaps with only 18 CpG islands (0.56% of TDG recruited sites, figure 
3.3D). The most abundant de novo motif identified within TDG binding sites is a purine-
rich sequence consisting of RGGAGRNNRAGR (R=purines; Figure 3.4). Interestingly, 
motifs of transcription factors with roles in TGFβ gene expression such as SNAIL, SP1, 
Yin Yang 1 (YY1), ZEB1, v-ets avian erythroblastosis virus E26 oncogene homolog 1 
(ETS1), ID1, and NF-kappaB were all significantly enriched (p<0.05) within TDG 
recruited sites (Table 3.1).  
To identify changes in DNA methylation following a 3 hr TGFβ treatment, 
MeDIP-Seq was performed using a specific 5mC antibody. Approximately 200 million 
reads were sequenced which were subsequently aligned to the human genome. 75,043 
DMRs in either control or treatment were identified using an FDR of 0.001 and a window 
size of 200 base pairs. 
A DMR was scored to the sample that had a higher methylation level (i.e. if a 
region has reduced methylation after TGFβ treatment, the DMR was scored to the control 
sample).  Comparison of DMRs at different fold change cut-offs revealed that the control 
sample had over 10 fold more DMRs than the TGFβ sample, thus confirming the global 
methylation decrease observed by dot blot (Figure 3.5A). Using a 2.0 fold cut-off, 8230 
DMRs were scored in the control sample. These DMRs constituted the regions that lost 
methylation upon TGFβ treatment. The CDKN2B promoter exhibited a 1016 fold 
decrease in methylation, and this locus again demonstrated the highest fold change 
(Figure 3.5C). Importantly, the promoter of CDKN1A, which was also shown to undergo 
a TGFβ-dependent decrease in methylation (Thillainadesan et al., 2012), had a 2.5 fold 
decrease in methylation and provided a second positive control for the assay. 
Demethylated regions in individual chromosomes was not dependent on chromosome 
size, suggesting that these events were not random (Figure 3.5B). Akin to the TDG ChIP-
Seq, chromosome 9 has the greatest number of DMRs. Comparison of DMRs to CpG 
islands revealed an overlap of 1055 DMRs with CpG islands (12.8% of DMRs, Figure 
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3.5D). Analysis of known transcription factor motifs in the 8230 DMRs revealed 53 
motifs that were significantly enriched in demethylated regions (Table 3.2). Many of 
these were shared with TDG recruited sites, but also included uniquely enriched motifs, 
such as MYC and MAX. 
Based on the relationship between TDG recruitment and TGFβ dependent 
demethylation at the CDKN2B promoter (Thillainadesan et al., 2012), I anticipated a 
substantial overlap between TDG binding sites and DNA demethylation. Surprisingly, 
comparison of the 3364 TDG binding sites with the 8230 DMRs identified only 11 
overlapping genomic locations. This suggests that the overlap in TDG recruitment at 
rapidly demethylated regions following TGFβ treatment is minimal in HaCaT cells.  
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Figure 3.2. Experimental strategy designed to assess the role of TDG in TGFβ-
dependent gene expression and methylation in HaCAT cells. HaCAT cells were 
grown to 60% confluency, synchronized by serum starvation, and then treated with or 
without TGFβ (5ng/mL) for the indicated time points.   
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Figure 3.3. Genome-wide analysis of TDG recruitment in TGFβ treated HaCaT 
cells. ChIP-Seq was conducted in control and TGFβ treated (90 minutes) HaCaT cells. 
Peaks were determined using an FDR of 0.01 and a window size of 200 bps. A) The 
number of TDG peaks that have the indicated scaled fold changes. Scaled fold change 
compares the intensity of signal of the TGFβ sample to the untreated sample. B) The 
number of increased TDG peaks (>2 fold) on each chromosome was plotted against 
chromosome size. Labels beside each data point represent the chromosome number. C) 
Representative image of TDG ChIP-Seq peaks on the CDKN2B promoter. The arrow 
indicates the TSS and direction of transcription. D) Venn diagram comparing TDG 
recruited sites with known CpG islands. 
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Figure 3.4. De novo motifs identified in TDG recruited sites. De novo motifs were 
identified in TDG recruited sites using Partek. Shown are the top 5 motifs and their 
corresponding log likelihood ratio.   
36 
 
 
 
 
 
37 
 
 
 
 
 
 
 
 
 
Table 3.1. Enrichment of transcription factors motifs in TDG binding sites. 
Increased TDG peaks were analyzed by Partek for over-representation of transcription 
factor motifs found within the JASPAR database. Listed are all the enriched motifs that 
contained a p-value less than 0.05. 
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Figure 3.5. Genome-wide analysis of TGFβ-dependent changes in 5mC. Methylated 
MeDIP-Seq was performed in control and TGFβ treated (5ng/mL for 3 hours) HaCaT 
cells using a 5mC antibody. DMRs in either treated or control samples were determined 
by Partek using a false discovery rate of 0.001 and a window size of 200 bps. DMRs 
were scored to the sample that had the higher methylation (i.e. if methylation was lost 
upon treatment, the DMR is scored in the control sample and vice versa). A) The number 
of DMRs in either treatment or control that have the indicated fold changes of 
methylation loss. B) The number DMRs on each chromosome was plotted against 
chromosome size. Labels beside each data point represent the chromosome number. C) 
Representative image of MeDIP-Seq peaks on the CDKN2B promoter. The arrow 
indicates the TSS and direction of transcription. D) Venn diagram comparing DMRs with 
CpG islands.   
40 
 
 
 
 
41 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2. Enrichment of transcription factor motifs in TGFβ-dependent regions 
with methylation loss. DMRs were analyzed for over representation of transcription 
factor motifs found within the JASPAR database. Listed are all the enriched motifs that 
contained a p-value less than 0.05. 
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3.3 Identification of TGFβ regulated genes 
In order to gain a better understanding of the relationship between TDG binding, 
DNA demethylation, and TGFβ induced gene expression, RNA-Seq was conducted in 
HaCaT cells treated with vehicle or TGFβ for 3h and 16h. These time points were chosen 
to generate a list of genes where: (A) increased transcription would be detected early (3 
hours), at a similar time point to the ChIP-Seq and MeDIP-Seq, and (B) similar genes 
would continue to be upregulated at a later time point (16 hours). This is based on the 
assumption that recruitment of transcriptional activators and/or removal of a repressive 
mark, such as 5mC, generates a strong and persistent transcriptional response to TGFβ. 
Furthermore, genes upregulated at both time points would provide a confident list of 
TGFβ upregulated genes.   
Normalized read counts on each gene were compared between TGFβ and control 
to identify genes that were up or down regulated at each time point. Using cut-offs of 1.5 
fold at both time points, 440 genes were upregulated and 387 were downregulated 
(Figure 3.6A). This list included several well-studied TGFβ target genes, such as 
CDKN2B, serpin peptidase inhibitor, clade E, member 1 (SERPINE1), SMAD7, ID1, and 
ID2 (Figure 3.6B). Gene ontology (GO) analysis of the 440 upregulated genes indicate 
several significantly enriched terms, including cell adhesion, angiogenesis, and 
extracellular matrix (Figure 3.6C). Five novel TGFβ regulated genes were validated by 
qPCR: SIRPA (signal-regulatory protein alpha), PDZK1 (PDZ domain containing 1), and 
PIK3IP1 (phosphoinositide-3-kinase interacting protein 1) were upregulated by TGFβ, 
while TDG, IFIT2 (interferon-induced protein with tetratricopeptide repeats 2), and 
EREG (epiregulin) were downregulated (Figure 3.7).   
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Figure 3.6. Differential RNA expression analysis of TGFβ treated HaCaT cells. 
HaCaT cells were treated with TGFβ (5ng/mL) for 3 and 16 hours. RNA was collected, 
converted to cDNA and subjected to high throughput sequencing. Analysis was 
conducted by Partek using the RefSeq database to annotate transcripts. A) Number of 
genes upregulated (top) or downregulated (bottom) and the respective fold changes for 
each time point and the number of genes that are common between the time points at the 
fold changes indicated. B) List of known TGFβ regulated genes and their fold changes at 
each time point. C) GO analysis of genes that are upregulated 1.5 fold at both 3 and 16 
hours (440 genes). To the right of each data point is the associated enrichment p-value. 
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Figure 3.7. Validation of novel TGFβ dependent genes. HaCaT cells were treated with 
vehicle or 5ng/mL TGFβ for 3 or 16 hours. RNA was isolated, converted to cDNA, and 
analyzed by SYBR green based qPCR with primers designed against the indicated 
mRNA. Values shown are mean plus SD TGFβ values that are relative to the control 
sample of each time point and normalized to GAPDH for three independent experiments. 
Asterisks indicate the p-value (*=<0.05, **=<0.01, ***=<0.001) obtained using a paired, 
two tailed t-test between treatment and control for each time point. 
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3.4 Identification of TGFβ induced genes potentially regulated by TDG or loss of 
methylation 
The minimal overlap between TDG binding and DNA demethylation suggests 
that TDG may have additional roles in TGFβ signaling, based on the time points used. 
Indeed, TDG can regulate gene expression as a transcriptional coactivator independent of 
its role in active demethylation (Chen et al., 2003; Tini et al., 2002; Um et al., 1998). 
Thus, I decided to analyze TDG recruitment separately from demethylation while 
investigating potential TGFβ target genes.  
To identify potential TDG-dependent genes in TGFβ signaling, I compared TGFβ 
upregulated genes identified using RNA-Seq with genome-wide TDG recruitment. I 
identified 40 upregulated genes which contained at least one TDG binding site 50 kb 
upstream of a TSS. To assess the distribution of TDG binding along these genes, each 
gene locus was divided into regions categorized as distal (50 kb upstream to 5 kb 
upstream of TSS), promoter (5 kb upstream to 3 kb downstream of TSS), 5’UTR, coding 
sequence (CDS), and 3’UTR. Approximately, 52.8% of binding was found within CDS, 
34.7% in the distal region, 9.7% in the promoter, and 1.4% in both the 5’UTR and 3’UTR 
regions (Figure 3.8A). Top GO terms for potential TDG regulated genes include 
interstitial matrix, cell adhesion, extracellular matrix organization, and cell growth 
(Figure 3.8B).  
To confirm this analysis, several of these genes were validated using conventional 
ChIP-qPCR (Figure 3.9).  These included: (1) a distal region of the matrix 
metallopeptidase 9 (MMP9) locus (-35186 bps away from TSS), (2) a previously 
characterized TGFβ responsive enhancer element that controls collagen, type IV, alpha 1 
(COL4A1) and COL4A2 transcription (-4652 bps away from TSS; Sumi et al., 2007), (3) 
a distal region of hyaluronan synthase 2 (HAS2) (-8311 bps away from TSS), and (4) a 
promoter region of adenylate kinase 8 (AK8) (+1597 bps away from TSS).  
Methylation changes in the absence of TDG recruitment are potential sites of 
TET-dependent oxidation of 5mC, or an alternative mechanism that removes or changes 
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5mC. Regardless of the mechanism, these sites are of interest because of the role of 5mC 
in regulating transcription. To identify TGFβ upregulated genes that undergo DNA 
demethylation, I compared the 440 upregulated genes with the 8230 DMRs identified 
using MeDIP. This analysis revealed 169 TGFβ upregulated genes that had at least one 
DMR present from 50 kb upstream of a TSS to the end of the transcript. Of the DMRs 
that were found in the locus of an upregulated gene, 39.8% were in the distal region, 
36.1% in the CDS, 16.2% in the promoter, 5.09% in the 5’ untranslated region (UTR), 
and 2.7% in the 3’UTR (Figure 3.10A).  
Notably, demethylation was found on several canonical TGFβ target genes, 
including: SERPINE1, growth arrest and DNA damage inducible beta (GADD45B), 
transforming growth factor beta induced (TGFBI), SKI-like proto-oncogene (SKIL) and 
several others (Figure 3.10B). The top GO terms in this gene list included positive 
regulation of transcription from RNA polymerase II promoter, transforming growth 
factor beta receptor signaling pathway, and cell motility (Figure 3.10C). For one of the 
genes identified, tropomyosin 1 (TPM1), a tumour suppressor, methylation of its 
promoter has been shown to prevent TGFβ-dependent upregulation in metastatic cancer 
cells (Varga et al., 2005).  Interestingly, 10 genes in the list have been reported to exhibit 
promoter hypermethylation in at least one type of cancer (Table 3.3), and suggests that 
the contribution of DNA methylation to TGFβ resistance is more widespread. 
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Figure 3.8. Analysis of TDG recruitment at TGFβ upregulated genes. Binding sites 
for TDG were annotated to a gene locus if the peak was located within 50 kb upstream of 
the TSS to the end of the transcript. Forty TGFβ upregulated genes contained at least one 
TDG binding site. A) Gene loci were divided into five distinct regions and scored for the 
presence of a TDG peak: Distal (-50 kb to -5 kb from TSS), Promoter (-5 kb to +3 kb 
from TSS), 5’UTR, CDS, and 3’UTR. B) GO analysis of the 40 genes potentially 
regulated by TDG. Beside each data point is the associated enrichment p-value.    
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Figure 3.9. Validation of TDG binding at TGFβ upregulated genes. HaCaT cells were 
treated with vehicle or with 5ng/mL TGFβ for 90 minutes. ChIP analysis was performed 
with a TDG-specific antibody. The DNA was analyzed using qPCR primers designed 
against regions identified in the TDG ChIP-Seq experiment. IgG control values for ChIP 
were subtracted from values obtained using TDG antibody. Error bars indicate standard 
error of the mean (n=2).   
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Figure 3.10. Analysis of TGFβ upregulated genes that exhibited methylation loss 
within the locus. DMRs were annotated to a gene locus if the region was located within 
50 kb upstream of the TSS to the end of the transcript. One hundred and sixty nine TGFβ 
upregulated genes contained at least one DMR. A) Gene loci were divided into five 
distinct regions and scored for the presence of a DMR: Distal (-50 kb to -5 kb from TSS), 
Promoter (-5 kb to +3 kb from TSS), 5’UTR, CDS, and 3’UTR. B) List of previously 
characterized TGFβ regulated genes that exhibited a methylation loss and the distance of 
the DMR to the TSS. C) GO analysis of the 169 genes potentially regulated by 
demethylation. Beside each data point is the associated enrichment p-value.  
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Table 3.3. Genes with reported promoter hypermethylation in cancer that were 
induced by TGFβ and had decreased methylation at or near their promoter in 
HaCaTs.   
57 
 
 
 
 
 
Gene Type of cancer(s) Reference(s) 
ADRA1B Gastric (Noda et al., 2007) 
C2CD4D Hepatocellular Carcinoma (Song et al., 2013c) 
CYP24A1 Prostate, HCV related Hepatocellular 
Carcinoma 
(Deng et al., 2010; Luo et al., 2010) 
FOXC2 Breast (Lindqvist et al., 2014) 
MAMDC2 Colorectal, Lung adenocarcinoma  (Mitchell et al., 2014; Selamat et al., 2012) 
MSC  Lymphomas (Ushmorov et al., 2008) 
PAX1 Cervical, oral 
squamous cell carcinoma 
(Huang et al., 2013; Nikolaidis et al., 
2015) 
PCDH8 Wilms’ tumour (Dallosso et al., 2009) 
TAGLN Hepatocellular Carcinoma, Ovarian (Hirasawa et al., 2006; Matsumura et al., 
2011)  
UNC13A Breast (Legendre et al., 2015) 
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3.5 Role of TDG in TGFβ growth inhibition and EMT 
The recruitment of TDG to potential regulatory regions of a number of genes 
suggests that it could be important for transcription changes leading to the pleiotropic 
responses elicited by TGFβ stimulation. HaCaT cells have been extensively used as a 
model system to study TGFβ stimulated growth inhibition and an EMT-like induction 
(Gomis et al., 2006; Kortlever et al., 2008; Lamouille and Derynck, 2007; Wang et al., 
2012). To assess if TDG is required for these two TGFβ responses, I compared the 
growth inhibition and EMT induction in HaCaT cells transiently transfected with siRNA 
targeting TDG or a scrambled siRNA.  
Prior to conducting the knockdown experiments, I analyzed TDG mRNA and 
protein levels during TGFβ treatment to assess if TDG is regulated by TGFβ. RNA and 
protein was collected every 24 hours from HaCaT cells treated with TGFβ or vehicle for 
72 hours. TDG mRNA levels were decreased by approximately 50% in TGFβ treated 
cells compared to vehicle. (Figure 3.11B). This was consistent with the RNA-Seq, where 
TDG mRNA levels were decreased 1.12 fold at 3 hours and 1.76 fold at 16 hours. 
Surprisingly, while mRNA levels were decreased in TGFβ treated cells compared to 
control, TDG protein levels increased following TGFβ treatment and remained increased 
for the duration of the experiment (Figure 3.11A and B). These results suggest that TDG 
may be regulated transcriptionally and/or post-transcriptionally by TGFβ, which point to 
TDG being an important player in TGFβ signaling.      
Previously, it was shown that TDG knockdown in HaCaT cells prevented full 
induction of CDKN2B mRNA, as assessed by qPCR (Thillainadesan et al., 2012). I was 
able to confirm this result at the protein level as well (Figure 3.12). As p15 is involved in 
TGFβ growth inhibition and its protein levels are reduced in siTDG cells, I reasoned that 
the loss of TDG would impact the ability of cells to undergo TGFβ growth inhibition. To 
assess if TDG is necessary for TGFβ growth inhibition, I performed a growth curve assay 
using HaCaT cells transfected with siControl or siTDG. In unstimulated cells, both 
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siControl and siTDG cells exhibited exponential growth, although siTDG cells grew 
noticeably faster than siControl cells (Figure 3.12A). However, with TGFβ, both 
siControl and siTDG cells had reduced growth relative to their respective vehicle 
condition, suggesting that TDG knockdown did not impair TGFβ’s growth inhibition 
response in HaCaT cells. TGFβ also causes growth arrest in mouse embryonic fibroblasts 
(MEFs). My lab derived MEFs from Tdgflox/flox;UB-Cre/ERT2+ mice. Treatment of these 
MEFs with tamoxifen activates the Cre recombinase, which excises a TDG coding 
sequence preventing protein production. To test the requirement for TDG in TGFβ 
induced growth arrest in MEFs, a growth curve assay was conducted in tamoxifen pre-
treated and untreated Tdgflox/flox;UB-Cre/ERT2+ MEFs treated with or without TGFβ. 
Similar to what occurs in HaCaT cells, TDG depletion did not impact TGFβ induced 
growth inhibition (Figure 3.12B). Interestingly, the TDG protein upregulation by TGFβ 
observed in HaCaT cells also occurred in the control MEFs (Figure 3.12B).  
The ChIP-Seq analysis indicated that TDG is recruited to genes implicated in cell 
adhesion and extracellular matrix organization. Furthermore, transcription factor binding 
motifs involved in EMT are enriched in TDG recruited sites. Therefore, I examined the 
potential role of TDG in EMT induction. A TGFβ dependent EMT response in HaCaT 
cells was observed as a morphological change in the cells from a cuboidal shape with 
tight contact to an elongated shape with cell spreading. In addition, downregulation of E-
Cadherin and upregulation of N-Cadherin confirmed the EMT response (Figure 3.13A).  
 
I observed that TDG reduction alone resulted in a morphology change such that the cells 
become more spindle shaped and were more spread out (Figure 3.13B, left). Assessing 
the levels of the epithelial marker, E-Cadherin, revealed that it was slightly decreased in 
siTDG cells compared to siControl, while no change was observed with the mesenchymal 
marker N-Cadherin (Figure 3.13B, right). The significance behind these changes is 
currently unclear, although it may indicate that TDG is necessary for maintaining the 
normal epithelial status of HaCaT cells. Next, siControl and siTDG were treated with 
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TGFβ to see if the reduction in TDG impacts EMT induction in HaCaT cells. Despite the 
change in morphology of siTDG cells, no major difference was observed in EMT 
induction after a 48 hour TGFβ treatment between siControl and siTDG HaCaT cells 
(Figure 3.13C). 
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Figure 3.11. TDG is regulated transcriptionally and post-transcriptionally by TGFβ. 
HaCaT cells were treated with vehicle or 5ng/mL TGFβ for 72 hours. Protein and RNA 
was isolated at the time of treatment (time 0) and every 24 hours after treatment. A) 
Immunoblot of the protein samples probed with the indicated antibodies. The 
immunoblot shown is representative of three independent experiments. B) Protein: TDG 
bands were quantified and normalized to vinculin. RNA: RNA was isolated, converted to 
cDNA, and analyzed by SYBR green qPCR with primers against TDG mRNA and 
normalized with GAPDH primers. For each time point, the TGFβ value is relative to the 
vehicle. Shown are means +SD of at least three independent experiments. Asterisks 
indicate the p-value (*=<0.05, **=<0.01, ***=<0.001) obtained using a paired, two tailed 
t-test between treatment and control for each time point. 
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Figure 3.12. Depletion of TDG prevents p15 expression but does not impair TGFβ 
induced growth inhibition in HaCaTs or MEFs. A) 72 hours post TDG knockdown by 
siRNA, HaCAT cells were plated at equal density and treated with vehicle or TGFβ for 
72 hours. Left, Representative immunoblot analysis of protein extracted at the 24 hour 
time point. Right, Cell number was counted every 24 hours to generate a growth curve 
(n=2). B) Tdgflox/flox;UB-Cre/ERT2+ MEFs were treated with or without tamoxifen to 
activate Cre recombinase leading to Tdg excision. Following tamoxifen treatment, MEFs 
were seeded and treated with or without TGFβ for 72 hours. Left, Representative 
immunoblot analysis of protein extracted at the 48 hour time point. Right, Cell number 
was counted every 24 hours to generate a growth curve (n=1).   
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Figure 3.13. siRNA knockdown of TDG in HaCaT cells does not impact EMT 
induction by TGFβ. A) EMT induction by TGFβ in HaCaT cells. Protein was harvested 
from HaCaT cells treated with vehicle or TGFβ for 72 hours and immunoblotted with the 
indicated antibodies. B) TDG knockdown changes the epithelial status of HaCaT cells. 72 
hours post knockdown, an image of the cells was taken using a phase contrast microscope 
and protein was harvested and immunoblotted with the indicated antibodies. C) HaCaT 
cells in (B) were treated with vehicle or TGFβ for 48 hours. Protein was harvested and 
immunoblotted with the indicated antibodies.       
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4 Discussion 
4.1 Overview 
The response to TGFβ involves a complex signaling and gene regulatory network 
of transcription factors, coregulators, and chromatin modifiers that regulate hundreds of 
genes in a cell-type specific manner (Massagué, 2012). While work on the pathway has 
focused primarily on epigenetic changes involving histone modifications, a complete 
understanding of the dynamics of DNA methylation in this pathway has not been 
addressed. Recent studies by our lab have demonstrated a rapid loss of DNA methylation 
at the CDKN2B and CDKN1A promoters in response to TGFβ (Thillainadesan et al., 
2012). Interestingly, TGFβ stimulated recruitment of TDG to the CDKN2B promoter and 
knockdown of TDG impaired DNA demethylation. These findings suggested that TDG 
has a crucial role in active demethylation. Using genome-wide approaches, I have 
attempted to characterize the relationship between TGFβ induced DNA demethylation 
and changes in gene expression in HaCaT cells. 
4.2 Global approach to identify locations of TDG recruitment and methylation 
loss 
To extend the studies using the CDKN2B gene locus, ChIP-Seq, using a TDG 
specific antibody, and MeDIP-Seq were used to identify additional locations of TGFβ-
dependent TDG recruitment and methylation loss, respectively. My analysis identified 
several interesting correlations with respect to TGFβ-dependent TDG recruitment and 
DNA demethylation. First, chromosome 9 had over three times as many TDG recruitment 
sites as any other chromosome, which suggests that factors responsible for TDG 
recruitment are enriched on chromosome 9. Also, there was some overlap ( ̴ 1000 sites, 
12.8% of DMRs) between methylation loss and CpG islands, whereas TDG binding at 
CpG islands was minimal (18 sites, 0.54% of TDG binding). CpG islands in somatic cells 
are typically devoid of methylation, so it is not surprising that a high percentage of TDG 
binding and DMRs occur away from CpG islands. 
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Another interesting result is that numerous transcription factor motifs were 
enriched within TDG binding sites and DMRs. This result suggests that TGFβ-dependent 
TDG binding and demethylation occur frequently at transcriptional regulatory elements. 
Of interest, SP1 was very significantly enriched in both datasets. This transcription factor 
has a GC-rich consensus sequence of GGGCGG and methylation of CG in the binding 
site interferes with DNA binding on some promoters (Clark et al., 1997; Douet et al., 
2007; Mulero-Navarro et al., 2006; Tian et al., 2015). This is also the case for YY1, 
which has a CG in its putative motif and was significantly enriched in both datasets (Kim 
et al., 2003; Sekimata et al., 2011). The enrichment of Spi-1 proto-oncogene (SPI1, also 
known as PU.1) in both datasets is also interesting. This transcription factor has been 
shown to interact with TET2 and DNMT3B, and the SPI1 motif was enriched in genomic 
regions undergoing methylation changes during monocyte-to-osteoclast differentiation 
(de la Rica et al., 2013). These discoveries support further investigation into potential 
relationships between SP1, YY1, and SPI1 with DNA demethylation processes in TGFβ 
signaling. 
4.3 Minimal overlap between TDG recruitment and DMRs 
A major goal of this study was to identify the genome-wide overlap between TDG 
binding and DNA demethylation, as this would reveal other targets of TDG mediated 
DNA demethylation. It is unlikely that the 11 identified genomic locations where TDG 
recruitment and demethylation overlap in this study would account for the global 
requirement for TDG observed by dot blot in Thillainadesan et al. One possibility for this 
is that the ChIP-Seq is performed at one time point, and can only provide a ‘snapshot’ of 
TDG binding. TDG binding may be very dynamic and could require multiple time points 
to get a true characterization of its recruitment. Also, the resolving power of MeDIP-Seq 
is lower than bisulphite sequencing, and any methylation change at a single CpG in a 
heavily methylated region may not be scored as methylation loss. A final limitation of the 
study is the possibility that TDG mediated DNA demethylation occurs in repetitive 
elements. During data analysis of the ChIP-Seq and MeDIP-Seq screens, reads that 
ambiguously align, such as repetitive elements, are discarded. As 5mC, 5fC, and 5caC are 
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enriched at major satellite repeats in mESCs (Shen et al., 2013), methylation changes and 
TDG recruitment could be occurring at these repetitive elements that went unaccounted 
for in this study. 
Additional factors with potential roles in DNA demethylation may also be 
responsible for the global DNA methylation changes. The dot blot analysis showed a 
TGFβ-dependent decrease in 5mC and 5hmC and an increase in 5fC. The AID/APOBEC 
mechanism could be responsible for reduced levels of 5mC and 5hmC by TGFβ by 
converting these modifications to thymine and 5hmU, respectively. Also, increased TET 
activity could explain the increased 5fC and decreased 5mC/5hmC. Increased TET 
activity would convert 5mC and 5hmC to 5fC or 5caC. Furthermore, there was evidence 
of both of these processes on the CDKN2B promoter (Thillainadesan et al., 2012). To test 
these possibilities, knocking down TET proteins and AID/APOBEC in HaCaT cells and 
treating with TGFβ followed by dot blot analysis of the metabolites would be 
informative. If positive, ChIP-Seq could be performed with antibodies against these 
proteins to see if their binding overlaps with methylation changes. 
4.4 Potential TDG-dependent TGFβ regulated genes 
Long before its role in DNA demethylation was realized, TDG was found to 
function as a transcriptional coactivator (Cortázar et al., 2011; Xu et al., 2015). Thus, 
TDG may fulfill an important transcriptional coregulator function in TGFβ signaling. 
Comparison of binding with TGFβ upregulated genes revealed 40 potential genes that 
TDG may regulate during TGFβ signaling. The majority of TDG binding occurred 
several kb away from the TSS, raising the possibility that TDG is recruited to distal 
regulatory elements. For example, TDG recruitment occurred at a previously identified 
TGFβ responsive enhancer that controls COL4A2 transcription (Sumi et al., 2007). 
Through its association with numerous transcription factors, particularly CBP, TDG 
recruitment could have an important function in the activation of these putative enhancer 
elements. Furthermore, there are multiple studies demonstrating that active DNA 
demethylation involving TDG occurs at some enhancers (Cortellino et al., 2011; Raiber 
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et al., 2012; Song et al., 2013b). Unfortunately, TGFβ enhancer elements in HaCaT cells 
have not been characterized, preventing a thorough understanding of TDG recruitment at 
these sites. 
4.5 Potential TGFβ target genes regulated by DNA demethylation 
Active demethylation has been documented for several signaling pathways such 
as estrogen (Métivier et al., 2008), retinoic acid (Le May et al., 2010), T cell activation 
(Bruniquel and Schwartz, 2003), glucocorticoid (Wiench et al., 2011), and TGFβ 
(Thillainadesan et al., 2012). In this study, I have identified 169 candidate genes where 
DNA demethylation may contribute to the regulation of those genes by TGFβ, suggesting 
that DNA demethylation is involved in transcriptional induction of a subset of genes. 
Strikingly, these DNA demethylation changes occurred at several canonical TGFβ target 
genes, including SERPINE1, GADD45B, TGFBI, SKIL, and MMP9. However, for the 
majority of genes demethylation was found several kilobases away from the TSS. 
Interestingly, active DNA demethylation at enhancer elements is common (Song and He, 
2013), and DNA methylation levels at enhancers is often a better indication of expression 
levels than promoter methylation (Aran and Hellman, 2013). Therefore, the methylation 
changes observed in this study could represent important regulatory events in TGFβ 
signaling. It would be interesting to test the requirement of the TET proteins and 
AID/APOBEC in growth inhibition and EMT in response to TGFβ, as these are likely 
candidates involved in initiating the methylation changes.  
Ten genes, including TPM1, exhibited a TGFβ-dependent methylation loss in 
their respective promoters. These genes have also been found hypermethylated in some 
cancers. TPM1 is a tumour suppressor gene that is induced by TGFβ only in metastatic 
cancer cells when its promoter is unmethylated (Varga et al., 2005). If methylation 
prevents TGFβ induction in cancer cells for the other genes identified, this may 
demonstrate a common feature in cancer cells that alters their responsiveness to TGFβ. 
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4.6 TGFβ regulation of TDG mRNA and protein levels 
I observed that TDG protein levels increased while its mRNA decreased in 
response to TGFβ, suggesting that TDG appears to be regulated at multiple levels. TDG 
transcription is directly upregulated by c-MYC in MCF10 cells (Bott et al., 2015). Thus, 
downregulation of c-MYC by TGFβ may account for the decreased TDG mRNA levels. 
Additionally, YY1, lymphoid enhancer-binding factor 1 (LEF1), cAMP responsive 
element binding protein (CREB), and signal transducer and activator of transcription 1 
(STAT1) transcription factor motifs are on the TDG promoter and may also mediate 
downregulation of TDG mRNA by TGFβ. 
 In contrast to mRNA levels, a surprising result was the increase of TDG protein in 
TGFβ treated cells compared to control. The most likely explanation for this result is 
post-translational mechanisms that regulate TDG protein stability. TDG is known to be 
regulated by post-translational modifications, including phosphorylation, acetylation, and 
sumoylation (Hardeland et al., 2002; Madabushi et al., 2013; Mohan et al., 2009). 
However, these studies have not shown an impact of these modifications on stability or 
expression of TDG protein. TDG levels are also regulated in a cell-cycle dependent 
manner. TDG is rapidly degraded in cells entering S phase by a mechanism that involves 
the ubiquitin proteasome system, while all other stages of the cell cycle express high 
amounts of TDG (Hardeland et al., 2007). Thus, an increase in TDG levels may be a 
consequence of G1/S phase arrest induced by TGFβ, which would result in an 
accumulation of TDG protein. 
4.7 Role of TDG in TGFβ growth inhibition and EMT induction 
In HaCaT cells, TGFβ causes a strong growth inhibition primarily through 
upregulation of cyclin dependent inhibitors and repression of MYC and ID1/2 (Pardali 
and Moustakas, 2007). Previous work (Thillainadesan et al., 2012) and the results 
presented in this study, have shown that TDG is critical for the induction of CDKN2B by 
TGFβ. Despite this, loss of TDG was not sufficient to prevent TGFβ growth inhibition. 
This may be attributed to functional redundancies, as TGFβ can still induce growth 
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inhibition in cells lacking CDKN2B (Latres et al., 2000). I also investigated the role of 
TDG in EMT induction in HaCaT cells. Although the legitimacy of EMT in HaCaT cells 
is controversial (Brown et al., 2004), the cells did exhibit an EMT-like response with 
TGFβ treatment. I initially predicted that loss of TDG would impair TGFβ induced EMT, 
since TDG recruitment was enriched with SNAIL and ZEB1 motifs and was found at 
genes involved in cell adhesion. However, I found that TDG depletion did not prevent 
TGFβ induced EMT in HaCaT cells. Many transcription factors are responsible for the 
transcriptional changes leading to TGFβ growth inhibition and EMT, thus, the loss of just 
TDG is likely not enough to impair the robustness of this response in HaCaT cells.  
Additional experiments are needed to completely understand the role of TDG in 
TGFβ signaling. Overexpressing TDG in cancer cells that are TGFβ insensitive would be 
an informative to assess changes in responsiveness to TGFβ. Finally, assessing the role of 
TDG in TGFβ’s regulation of ESC pluripotency would also be worthwhile given the role 
of TDG in embryogenesis and reprogramming (Cortázar et al., 2011; Hu et al., 2014), the 
finding that 5fC/5caC accumulate at active enhancers in ESCs in the absence of TDG 
(Shen et al., 2013; Song et al., 2013b), and the importance of enhancers in interpreting 
TGFβ signals in ESC differentiation (Beyer et al., 2013; Xi et al., 2011). 
4.8 Summary & future directions 
The major goal of this thesis was to assess how TDG mediated active 
demethylation affects TGFβ genome-wide. TDG ChIP-Seq and MeDIP-Seq experiments 
before and after TGFβ treatment in HaCaT cells revealed only 11 genomic locations 
where TDG recruitment overlaps with a methylation loss. Due to several limitations of 
the ChIP-Seq and MeDIP-Seq experiments, it is likely that this overlap is an 
underestimate of true TGFβ-dependent TDG DNA demethylation events. Other 
mechanisms involved in DNA demethylation, such as TET proteins and AID, may also 
be involved in global DNA demethylation by TGFβ. This is supported by the TGFβ-
dependent decrease in 5mC and 5hmC and increase in 5fC observed by dot blot. 
Clarification of these possibilities is an avenue for future work. 
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Comparison of the TGFβ upregulated genes to the ChIP-Seq and MeDIP-Seq 
screens revealed 40 potential TDG regulated genes and 169 genes potentially regulated 
by demethylation. Also, numerous transcription factor motifs were enriched at TDG 
binding sites and regions undergoing demethylation. Collectively, these results suggest 
that TDG and DNA demethylation could have important functions at transcriptional 
regulatory elements (e.g. enhancers) to regulate transcription of TGFβ target genes. 
Exploring the role of DNA methylation and TDG in controlling cell-type specific 
responses to TGFβ requires further investigation but could provide valuable insight into 
how TGFβ signals are interpreted in developmental and disease processes. 
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